1.Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes.
Mi Young LEE ; Jang Hyun KOH ; Soo Min NAM ; Pil Moon JUNG ; Joong Kyung SUNG ; Song Yi KIM ; Jang Yel SHIN ; Young Goo SHIN ; Choon Hee CHUNG
Yonsei Medical Journal 2008;49(6):901-908
PURPOSE: The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance, determined by a short insulin tolerance test (Kitt) in type 2 diabetic patients. PATIENTS AND METHODS: Eighty-three subjects (mean age = 57.87 +/- 10.78) with type 2 diabetes mellitus were enrolled and received daily one dose of rosiglitazone (4mg) or pioglitazone (15mg). The mean follow-up duration was 25.39 +/- 9.66 months. We assessed insulin sensitivity using HOMA-IR and the short insulin tolerance test before and after TZDs treatment. RESULTS: When we compared patients' characteristics before and after TZDs treatment, the mean fasting glucose level was significantly decreased (183.27 +/- 55.04 to 137.35 +/- 36.42mg/dL, p < 0.001) and the mean HbA1C level was significantly decreased (9.24 +/- 1.96 to 8.11 +/- 1.39%, p < 0.001). Also, Kitt values were significantly increased (2.03 +/- 1.14 to 2.67 +/- 0.97%/min, p = 0.003), whereas HOMA-IR was significantly decreased (2.98 +/- 0.68 to 1.04 +/- 0.24, p < 0.05). When classifying insulin resistance by Kitt values, insulin resistant subjects' values were increased (< 2.5%/min; 1.51 +/- 0.53%/min to 2.63 +/- 0.88, p < 0.001), whereas the values decreased in insulin sensitive subjects (> or = 2.5%/min; 3.50 +/- 0.75%/min to 2.75 +/- 1.12%/min, p = 0.002). CONCLUSION: The glucose lowering effects of TZDs by improving insulin resistance could be determined by using Kitt. However, Kitt may be a beneficial tool to determine TZDs' effects only when patients' Kitt values are less than 2.5%/min.
Aged
;
Blood Glucose/metabolism
;
Diabetes Mellitus, Type 2/blood/*diagnosis/*drug therapy
;
Drug Tolerance
;
Female
;
Humans
;
Hypoglycemic Agents/therapeutic use
;
Insulin/diagnostic use
;
*Insulin Resistance
;
Male
;
Middle Aged
;
Thiazolidinediones/*therapeutic use
2.Performance Characteristics of Glycated Albumin and Its Clinical Usefulness in Diabetic Patients on Hemodialysis.
Hae Il PARK ; Yeong Sic KIM ; Jehoon LEE ; Yonggoo KIM ; Seok Joon SHIN
The Korean Journal of Laboratory Medicine 2009;29(5):406-414
BACKGROUND: The HbA1c has been considered to underestimate glucose level in diabetic patients on hemodialysis, therefore, glycated albumin (GA) was recently introduced to assess the glycemic control for those cases. We evaluated the performance of GA assay kit of Lucica GA-L (Asahi Kasei Pharma Co., Japan) and compare it with HbA1c for estimating glucose levels. METHODS: Tests for precision, linearity and interference were performed and reference interval was determined. Thirty eight of non-hemodialysis and seventy of hemodialysis patients were recruited, whose glucose levels of three-, two- and one-month prior to this study were available for calculating weighted means of glucose (WMGs). The correlation coefficients and the slopes of regression equation between WMG and HbA1c or GA were compared between two groups. Multiple linear regression analyses were used to determine significant predictor for HbA1c and GA. RESULTS: Total CV was 2.2% at concentration of 13.7% and 2.8% at 24.6%. The dilution curve between 15.7% and 62.1% was linear. Reference intervals were 10.0% to 16.5% for male and 11.4% to 17.6% for female. The correlation coefficients between WMG and GA were 0.682-0.713 in hemodialysis and 0.640-0.677 in non-hemodialysis. Those between WMG and HbA1c were 0.568-0.625 in hemodialysis and 0.735-0.783 in non-hemodialysis. The slopes of regression equation between GA and WMG in hemodialysis were 0.080-0.090 and 0.130-0.147 in non-hemodialysis. Those between HbA1c and WMG in hemodialysis were 0.012-0.014 and 0.029-0.032 in non-hemodialysis. GA was not influenced by hemodialysis status while HbA1c was. CONCLUSIONS: The claimed performance characteristic of Lucica GA-L were verified. WMG were better reflected by GA rather than HbA1c in patients on hemodialysis.
Aged
;
Blood Glucose/chemistry
;
Diabetes Mellitus, Type 2/*diagnosis/metabolism/therapy
;
Female
;
Hemoglobin A, Glycosylated/analysis
;
Humans
;
Male
;
Middle Aged
;
Reagent Kits, Diagnostic
;
*Renal Dialysis
;
Reproducibility of Results
;
Serum Albumin/*analysis
3.The Effect of Early Insulin Therapy on Pancreatic beta-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients.
Suk CHON ; Seungjoon OH ; Sung Woon KIM ; Jin Woo KIM ; Young Seol KIM ; Jeong taek WOO
The Korean Journal of Internal Medicine 2010;25(3):273-281
BACKGROUND/AIMS: Based on the results of well designed clinical studies, intensive insulin therapy has been established to improve glycemic control in newly diagnosed diabetes. However, discrepancies exist between the findings of clinical trials and experiences in general practice. Furthermore, the efficacy of an early insulin therapy (EIT) - commonly used in general practice - on long-term glycemic control has not been established. Therefore, we evaluated the effects of EIT on pancreatic beta-cell function and glycemic control using insulin-based methods widely employed in general practice. METHODS: We performed a retrospective cohort study that initially involved reviewing patients' medical records. Following a thorough review, 61 patients who received either biphasic or prandial EIT at the time of diagnosis were enrolled. We then evaluated changes in beta-cell function and glycemic control during a 48-month follow-up period. RESULTS: Mean HbA1c decreased significantly as a result of EIT from 10.7 +/- 1.8% to 6.2 +/- 1.1% (p < 0.001). On average, 2.6 months was required to achieve an HbA1c value < 7%. EIT significantly improved the insulinogenic index. Glycemic control was well maintained for 48 months. More than 70% of patients were able to maintain glycemic control following lifestyle modifications or treatment with oral antidiabetic drugs. No significant differences were identified between patients receiving biphasic EIT and prandial EIT in terms of glycemic control or pancreatic beta-cell function. CONCLUSIONS: Our results suggest that regardless of the method of delivery, EIT significantly improves beta-cell function and facilitates long-term glycemic control in patients with newly diagnosed type 2 diabetes mellitus.
Administration, Oral
;
Adult
;
Blood Glucose/metabolism
;
Cohort Studies
;
Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/*physiopathology
;
Female
;
Hemoglobin A, Glycosylated/metabolism
;
Humans
;
Hypoglycemic Agents/administration & dosage
;
Insulin/administration & dosage/*therapeutic use
;
Insulin Resistance
;
Insulin-Secreting Cells/*drug effects/*physiology
;
Male
;
Middle Aged
;
Retrospective Studies
4.Incipient Albuminuria in Persons with Newly Diagnosed Type 2 Diabetes Mellitus: A 5-Year Retrospective Cohort Study.
Shermin TAN ; Lai Yin WONG ; Matthias Paul Hs TOH
Annals of the Academy of Medicine, Singapore 2018;47(12):502-508
INTRODUCTION:
This study aimed to determine the 5-year incidence of albuminuria among Asian persons with newly diagnosed type 2 diabetes mellitus (DM), and to identify the risk factors at diagnosis for progression to albuminuria.
MATERIALS AND METHODS:
A retrospective 5-year closed cohort study was conducted among 1016 persons aged ≥18 years old who were diagnosed with type 2 DM between 1 January 2007 and 31 December 2009 at primary care facilities in Singapore. The cumulative incidence of progression from normoalbuminuria to albuminuria-termed "progression"-was determined. The risk factors associated with progression were evaluated using multiple logistic regression analysis.
RESULTS:
A total of 541 (53.2%) participants were men. The mean (SD) onset age of type 2 DM was 54 (11) years. From diagnosis of type 2 DM, the 5-year cumulative incidence of progression was 17.3% and mean (SD) duration to progression was 2.88 (1.23) years. Higher onset age (OR 1.02; 95% CI, 1.00-1.04), history of hypertension (OR, 1.88; 95% CI, 1.32-2.70) and higher glycated haemoglobin (HbA1c) (OR, 1.17; 95% CI, 1.09-1.26) at diagnosis were associated with progression. In addition, being on angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) treatment at baseline modified the effect of hypertension on progression.
CONCLUSION
This study highlighted the importance of early screening and treatment of diabetes as well as prevention of hypertension, which could potentially delay the onset of microalbuminuria in persons with type 2 DM. Persons on ACEI or ARB treatment should continue to be monitored regularly for progression to albuminuria.
Adult
;
Age of Onset
;
Aged
;
Albuminuria
;
epidemiology
;
Angiotensin Receptor Antagonists
;
therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors
;
therapeutic use
;
Cohort Studies
;
Diabetes Mellitus, Type 2
;
diagnosis
;
epidemiology
;
metabolism
;
Disease Progression
;
Female
;
Glycated Hemoglobin A
;
metabolism
;
Humans
;
Hypertension
;
drug therapy
;
epidemiology
;
Logistic Models
;
Male
;
Middle Aged
;
Retrospective Studies
;
Risk Factors
;
Singapore
;
epidemiology
5.Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion.
Eun Ky KIM ; Tae Jung OH ; Lee Kyung KIM ; Young Min CHO
Journal of Korean Medical Science 2016;31(2):222-230
Dietary fiber improves hyperglycemia in patients with type 2 diabetes through its physicochemical properties and possible modulation of gut hormone secretion, such as glucagon-like peptide 1 (GLP-1). We assessed the effect of dietary fiber-enriched cereal flakes (DC) on postprandial hyperglycemia and gut hormone secretion in patients with type 2 diabetes. Thirteen participants ate isocaloric meals based on either DC or conventional cereal flakes (CC) in a crossover design. DC or CC was provided for dinner, night snack on day 1 and breakfast on day 2, followed by a high-fat lunch. On day 2, the levels of plasma glucose, GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and insulin were measured. Compared to CC, DC intake exhibited a lower post-breakfast 2-hours glucose level (198.5±12.8 vs. 245.9±15.2 mg/dL, P<0.05) and a lower incremental peak of glucose from baseline (101.8±9.1 vs. 140.3±14.3 mg/dL, P<0.001). The incremental area under the curve (iAUC) of glucose after breakfast was lower with DC than with CC (P<0.001). However, there were no differences in the plasma insulin, glucagon, GLP-1, and GIP levels. In conclusion, acute administration of DC attenuates postprandial hyperglycemia without any significant change in the representative glucose-regulating hormones in patients with type 2 diabetes (ClinicalTrials.gov. NCT 01997281).
Adult
;
Aged
;
Area Under Curve
;
Blood Glucose/*analysis
;
Cross-Over Studies
;
Diabetes Mellitus, Type 2/complications/diagnosis/*diet therapy
;
Dietary Fiber/*therapeutic use
;
Female
;
Gastric Inhibitory Polypeptide/blood
;
Glucagon/blood
;
Glucagon-Like Peptide 1/*blood
;
Hemoglobin A, Glycosylated/analysis
;
Humans
;
Hyperglycemia/complications/diagnosis
;
Insulin/blood
;
Intestines/metabolism
;
Male
;
Middle Aged
;
ROC Curve
6.Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes.
The Korean Journal of Internal Medicine 2015;30(1):6-16
Hypoglycemia is a major barrier to achieving the glycemic goal in patients with type 2 diabetes. In particular, severe hypoglycemia, which is defined as an event that requires the assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions, is a serious clinical concern in patients with diabetes. If severe hypoglycemia is not managed promptly, it can be life threatening. Hypoglycemia-associated autonomic failure (HAAF) is the main pathogenic mechanism behind severe hypoglycemia. Defective glucose counter-regulation (altered insulin secretion, glucagon secretion, and an attenuated increase in epinephrine during hypoglycemia) and a lack of awareness regarding hypoglycemia (attenuated sympathoadrenal activity) are common components of HAAF in patients with diabetes. There is considerable evidence that hypoglycemia is an independent risk factor for cardiovascular disease. In addition, hypoglycemia has a significant influence on the quality of life of patients with diabetes. To prevent hypoglycemic events, the setting of glycemic goals should be individualized, particularly in elderly individuals or patients with complicated or advanced type 2 diabetes. Patients at high-risk for the future development of severe hypoglycemia should be selected carefully, and intensive education with reinforcement should be implemented.
Autonomic Nervous System/physiopathology
;
Biological Markers/blood
;
Blood Glucose/*drug effects/metabolism
;
Diabetes Mellitus, Type 2/blood/complications/diagnosis/*drug therapy/physiopathology
;
Health Knowledge, Attitudes, Practice
;
Humans
;
Hypoglycemia/blood/chemically induced/epidemiology/physiopathology/*prevention & control
;
Hypoglycemic Agents/*adverse effects
;
Incidence
;
Patient Education as Topic
;
Prevalence
;
Prognosis
;
Risk Assessment
;
Risk Factors
7.Blood electrolyte disturbances during severe hypoglycemia in Korean patients with type 2 diabetes.
The Korean Journal of Internal Medicine 2015;30(5):648-656
BACKGROUND/AIMS: To investigate abnormalities in blood electrolyte levels during severe hypoglycemia in Korean patients with type 2 diabetes mellitus (T2DM) in a clinical setting. METHODS: Blood electrolyte levels in adult T2DM patients during severe hypoglycemia were collected from January 1, 2008 to December 31, 2012. Patients who maintained normal serum creatinine and blood urea nitrogen levels were utilized in the study. Severe hypoglycemia was defined as a condition requiring medical assistance, such as administering carbohydrates when serum glucose levels less than 70 mg/dL were observed, in conjunction with other symptoms of hypoglycemia. RESULTS: A total of 1,068 patients who visited the emergency room with severe hypoglycemia were screened, of which 219 patients were included in this study. The incidence of abnormal levels for any electrolyte was 47%. Hypokalemia (< 3.5 mmol/L) was the most common type of electrolyte disturbance observed at 21.9%. A decrease in serum potassium levels was associated with decreases in blood glucose levels (r = 0.151, p = 0.025). During severe hypoglycemia, median blood glucose levels, incidence of tachycardia (> 100 beats per minute) and severe hypertension (> or = 180/120 mmHg) were 30 mg/dL (range, 14 to 62) and 35 mg/dL (range, 10 to 69; p = 0.04), 18.8% and 7.2% (p = 0.02), and 20.8% and 10.2% (p = 0.05) in the hypokalemia and normokalemia groups, respectively. CONCLUSIONS: During severe hypoglycemia, hypokalemia occurred in 21.9% of T2DM patients and was associated with tachycardia and severe hypertension. Therefore, the results suggest that severe hypoglycemia may increase cardiovascular events in T2DM.
Aged
;
Aged, 80 and over
;
Biomarkers/blood
;
Blood Glucose/drug effects/*metabolism
;
Diabetes Mellitus, Type 2/blood/diagnosis/drug therapy/*epidemiology
;
Emergency Service, Hospital
;
Female
;
Humans
;
Hypertension/chemically induced/epidemiology
;
Hypoglycemia/blood/chemically induced/diagnosis/*epidemiology/therapy
;
Hypoglycemic Agents/adverse effects
;
Hypokalemia/blood/chemically induced/diagnosis/*epidemiology
;
Male
;
Middle Aged
;
Potassium/*blood
;
Republic of Korea/epidemiology
;
Risk Factors
;
Severity of Illness Index
;
Tachycardia/chemically induced/epidemiology
;
*Water-Electrolyte Balance/drug effects